Which item is included as a NDA component?

• A. Human pharmacokinetics and bioavailability
• B. Advertising copy
• C. Environmental assessment
• D. Patent status

Answer: (A)

The main idea here is that the regulatory submission for a new drug includes data on how the drug behaves in humans. Human pharmacokinetics and bioavailability are essential parts of the clinical pharmacology information in an NDA because they show how much of the drug reaches the bloodstream and how the drug is absorbed, distributed, metabolized, and excreted. This information defines exposure, helps set the correct dosing, and predicts how the drug will behave in different patients or with different formulations, which is crucial for ensuring safety and efficacy.

Advertising copy is promotional material, not a data component used to evaluate whether the drug should be approved. An environmental assessment, while sometimes relevant to regulatory actions under NEPA, is not a standard core component of the NDA package. Patent status relates to intellectual property and market protection, not the clinical and pharmacokinetic data reviewers use to assess safety and effectiveness.